P2X7 receptor inhibition protects against ischemic acute kidney injury in mice

American Journal of Physiology - Cell Physiology

Volumn 308, Issue 6, 2015, Pages C463-C472

  Yan, Yanli ^a,b   Bai, Jianwen ^a   Zhou, Xiaoxu ^b   Tang, Jinhua ^a,b   Jiang, Chunming ^b   Tolbert, Evelyn ^b   Bayliss, George ^b   Gong, Rujun ^b   Zhao, Ting C ^c   Zhuang, Shougang ^a,b  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b BROWN UNIVERSITY   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acute kidney injury; Apoptosis; Purinergic receptors; Renal tubular cells

Indexed keywords

3 [[5 (2,3 DICHLOROPHENYL) 1H TETRAZOL 1 YL]METHYL]PYRIDINE; ALPHA TUBULIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PURINERGIC P2X7 RECEPTOR; RANTES; 3-(5-(2,3-DICHLOROPHENYL)-1H-TETRAZOL-1-YL)METHYLPYRIDINE; ACUTE PHASE PROTEIN; AUTACOID; CCL2 PROTEIN, MOUSE; CCL5 PROTEIN, MOUSE; LCN2 PROTEIN, MOUSE; LIPOCALIN; MAPK1 PROTEIN, MOUSE; ONCOPROTEIN; P2RX7 PROTEIN, MOUSE; PURINERGIC P2X RECEPTOR ANTAGONIST; PYRIDINE DERIVATIVE; TETRAZOLE DERIVATIVE; URINARY TRACT AGENT;

ACUTE KIDNEY FAILURE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DEATH; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; INFLAMMATION; KIDNEY DYSFUNCTION; KIDNEY ISCHEMIA; KIDNEY PERFUSION; KIDNEY TUBULE DAMAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; RENAL PROTECTION; ACUTE KIDNEY INJURY; ANIMAL; CELL CULTURE; CELL PROTECTION; DISEASE MODEL; DRUG EFFECTS; GENETIC TRANSFECTION; GENETICS; KIDNEY; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHOSPHORYLATION; REPERFUSION INJURY; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTOR;

ACUTE KIDNEY INJURY; ACUTE-PHASE PROTEINS; ANIMALS; CELLS, CULTURED; CHEMOKINE CCL2; CHEMOKINE CCL5; CYTOPROTECTION; DISEASE MODELS, ANIMAL; INFLAMMATION MEDIATORS; KIDNEY; LIPOCALINS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; ONCOGENE PROTEINS; PHOSPHORYLATION; PURINERGIC P2X RECEPTOR ANTAGONISTS; PYRIDINES; RECEPTORS, PURINERGIC P2X7; REPERFUSION INJURY; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TETRAZOLES; TIME FACTORS; TRANSFECTION; UROLOGICAL AGENTS;

EID: 84980032037     PISSN: 03636143     EISSN: 15221563     Source Type: Journal    
DOI: 10.1152/ajpcell.00245.2014     Document Type: Article

References (46)

1. Adinolfi E, Raffaghello L, Giuliani AL, Cavazzini L, Capece M, Chiozzi P, Bianchi G, Kroemer G, Pistoia V, Di Virgilio F. Expression of P2X7 receptor increases in vivo tumor growth. Cancer Res 72: 2957–2969, 2012.
2. Alderliesten M, de Graauw M, Oldenampsen J, Qin Y, Pont C, van Buren L, van de Water B. Extracellular signal-regulated kinase activation during renal ischemia/reperfusion mediates focal adhesion dissolution and renal injury. Am J Pathol 171: 452–462, 2007.
3. Alves LA, Bezerra RJ, Faria RX, Ferreira LG, da Silva Frutuoso V. Physiological roles and potential therapeutic applications of the P2X7 receptor in inflammation and pain. Molecules 18: 10953–10972, 2013.
4. Arulkumaran N, Unwin RJ, Tam FW. A potential therapeutic role for P2X7 receptor (P2X7R) antagonists in the treatment of inflammatory diseases. Expet Opin Investig Drugs 20: 897–915, 2011.
5. Birch RE, Schwiebert EM, Peppiatt-Wildman CM, Wildman SS. Emerging key roles for P2X receptors in the kidney. Front Physiol 4: 262, 2013.
6. Bonventre JV, Yang L. Cellular pathophysiology of ischemic acute kidney injury. J Clin Invest 121: 4210–4221, 2011.
7. Booth JW, Tam FW, Unwin RJ. P2 purinoceptors: renal pathophysiology and therapeutic potential. Clin Nephrol 78: 154–163, 2012.
8. Chaitanya GV, Steven AJ, Babu PP. PARP-1 cleavage fragments: signatures of cell-death proteases in neurodegeneration. Cell Commun Signal 8: 31, 2010.
9. Chen L, Brosnan CF. Regulation of immune response by P2X7 receptor. Crit Rev Immunol 26: 499–513, 2006.
10. El-Achkar TM, McCracken R, Liu Y, Heitmeier MR, Bourgeois S, Ryerse J, Wu XR. Tamm-Horsfall protein translocates to the basolateral domain of thick ascending limbs, interstitium, and circulation during recovery from acute kidney injury. Am J Physiol Renal Physiol 304: F1066–F1075, 2013.
11. Gobeil S, Boucher CC, Nadeau D, Poirier GG. Characterization of the necrotic cleavage of poly(ADP-ribose) polymerase (PARP-1): implication of lysosomal proteases. Cell Death Differ 8: 588–594, 2001.
12. Goncalves RG, Gabrich L, Rosario A Jr, Takiya CM, Ferreira ML, Chiarini LB, Persechini PM, Coutinho-Silva R, Leite M Jr. The role of purinergic P2X7 receptors in the inflammation and fibrosis of unilateral ureteral obstruction in mice. Kidney Int 70: 1599–1606, 2006.
13. Gunosewoyo H, Kassiou M. P2X purinergic receptor ligands: recently patented compounds. Expert Opin Ther Pat 20: 625–646, 2010.
14. Havasi A, Borkan SC. Apoptosis and acute kidney injury. Kidney Int 80: 29–40, 2011.
15. Hillman KA, Burnstock G, Unwin RJ. The P2X7 ATP receptor in the kidney: a matter of life or death? Nephron Exp Nephrol 101: e24–30, 2005.
16. Hoque R, Sohail MA, Salhanick S, Malik AF, Ghani A, Robson SC, Mehal WZ. P2X7 receptor-mediated purinergic signaling promotes liver injury in acetaminophen hepatotoxicity in mice. Am J Physiol Gastrointest Liver Physiol 302: G1171–G1179, 2012.
17. Huang C, Yu W, Cui H, Wang Y, Zhang L, Han F, Huang T. P2X7 blockade attenuates mouse liver fibrosis. Mol Med Rep 9: 57–62, 2014.
18. Humphreys BD, Rice J, Kertesy SB, Dubyak GR. Stress-activated protein kinase/JNK activation and apoptotic induction by the macrophage P2X7 nucleotide receptor. J Biol Chem 275: 26792–26798, 2000.
19. Ji X, Naito Y, Hirokawa G, Weng H, Hiura Y, Takahashi R, Iwai N. P2X(7) receptor antagonism attenuates the hypertension and renal injury in Dahl salt-sensitive rats. Hypertens Res 35: 173–179, 2012.
20. Ji X, Naito Y, Weng H, Endo K, Ma X, Iwai N. P2X7 deficiency attenuates hypertension and renal injury in deoxycorticosterone acetatesalt hypertension. Am J Physiol Renal Physiol 303: F1207–F1215, 2012.
21. Jiang LH, Baldwin JM, Roger S, Baldwin SA. Insights into the molecular mechanisms underlying mammalian P2X7 receptor functions and contributions in diseases, revealed by structural modeling and single nucleotide polymorphisms. Front Pharmacol 4: 55, 2013.
22. Jo SK, Cho WY, Sung SA, Kim HK, Won NH. MEK inhibitor, U0126, attenuates cisplatin-induced renal injury by decreasing inflammation and apoptosis. Kidney Int 67: 458–466, 2005.
23. Kvist TM, Schwarz P, Jorgensen NR. The P2X7 receptor: a key player in immune-mediated bone loss? ScientificWorldJournal 2014: 954530, 2014.
24. Linkermann A, Chen G, Dong G, Kunzendorf U, Krautwald S, Dong Z. Regulated cell death in AKI. J Am Soc Nephrol 25: 2689–2701, 2014.
25. Linkermann A, De Zen F, Weinberg J, Kunzendorf U, Krautwald S. Programmed necrosis in acute kidney injury. Nephrol Dial Transplant 27: 3412–3419, 2012.
26. Linkermann A, Green DR. Necroptosis. N Engl J Med 370: 455–465, 2014.
27. Liu N, He S, Tolbert E, Gong R, Bayliss G, Zhuang S. Suramin alleviates glomerular injury and inflammation in the remnant kidney. PLoS One 7: e36194, 2012.
28. Lopez-Castejon G, Pelegrin P. Current status of inflammasome blockers as anti-inflammatory drugs. Expert Opin Invest Drugs 21: 995–1007, 2012.
29. Nelson DW, Gregg RJ, Kort ME, Perez-Medrano A, Voight EA, Wang Y, Grayson G, Namovic MT, Donnelly-Roberts DL, Niforatos W, Honore P, Jarvis MF, Faltynek CR, Carroll WA. Structure-activity relationship studies on a series of novel, substituted 1-benzyl-5-phenyltetrazole P2X7 antagonists. J Med Chem 49: 3659–3666, 2006.
30. Paragas N, Qiu A, Zhang Q, Samstein B, Deng SX, Schmidt-Ott KM, Viltard M, Yu W, Forster CS, Gong G, Liu Y, Kulkarni R, Mori K, Kalandadze A, Ratner AJ, Devarajan P, Landry DW, D’Agati V, Lin CS, Barasch J. The Ngal reporter mouse detects the response of the kidney to injury in real time. Nat Med 17: 216–222, 2011.
31. Peng W, Cotrina ML, Han X, Yu H, Bekar L, Blum L, Takano T, Tian GF, Goldman SA, Nedergaard M. Systemic administration of an antagonist of the ATP-sensitive receptor P2X7 improves recovery after spinal cord injury. Proc Natl Acad Sci USA 106: 12489–12493, 2009.
32. Ponnusamy M, Liu N, Gong R, Yan H, Zhuang S. ERK pathway mediates P2X7 expression and cell death in renal interstitial fibroblasts exposed to necrotic renal epithelial cells. Am J Physiol Renal Physiol 301: F650–F659, 2011.
33. Ponnusamy M, Ma L, Gong R, Pang M, Chin YE, Zhuang S. P2X7 receptors mediate deleterious renal epithelial-fibroblast cross talk. Am J Physiol Renal Physiol 300: F62–F70, 2011.
34. Rassendren F, Buell GN, Virginio C, Collo G, North RA, Surprenant A. The permeabilizing ATP receptor, P2X7. Cloning and expression of a human cDNA. J Biol Chem 272: 5482–5486, 1997.
35. Sun SH, Lin LB, Hung AC, Kuo JS. ATP-stimulated Ca2 influx and phospholipase D activities of a rat brain-derived type-2 astrocyte cell line, RBA-2, are mediated through P2X7 receptors. J Neurochem 73: 334–343, 1999.
36. Tang J, Liu N, Tolbert E, Ponnusamy M, Ma L, Gong R, Bayliss G, Yan H, Zhuang S. Sustained activation of EGFR triggers renal fibrogenesis after acute kidney injury. Am J Pathol 183: 160–172, 2013.
37. Taylor SR, Turner CM, Elliott JI, McDaid J, Hewitt R, Smith J, Pickering MC, Whitehouse DL, Cook HT, Burnstock G, Pusey CD, Unwin RJ, Tam FW. P2X7 deficiency attenuates renal injury in experimental glomerulonephritis. J Am Soc Nephrol 20: 1275–1281, 2009.
38. Turner CM, Tam FW, Lai PC, Tarzi RM, Burnstock G, Pusey CD, Cook HT, Unwin RJ. Increased expression of the pro-apoptotic ATPsensitive P2X7 receptor in experimental and human glomerulonephritis. Nephrol Dial Transplant 22: 386–395, 2007.
39. Vanmassenhove J, Vanholder R, Nagler E, Van Biesen W. Urinary and serum biomarkers for the diagnosis of acute kidney injury: an in-depth review of the literature. Nephrol Dial Transplant 28: 254–273, 2013.
40. Verhoef PA, Estacion M, Schilling W, Dubyak GR. P2X7 receptordependent blebbing and the activation of Rho-effector kinases, caspases, and IL-1 beta release. J Immunol 170: 5728–5738, 2003.
41. Vonend O, Turner CM, Chan CM, Loesch A, Dell’Anna GC, Srai KS, Burnstock G, Unwin RJ. Glomerular expression of the ATP-sensitive P2X receptor in diabetic and hypertensive rat models. Kidney Int 66: 157–166, 2004.
42. Wasylyk B, Hagman J, Gutierrez-Hartmann A. Ets transcription factors: nuclear effectors of the Ras-MAP-kinase signaling pathway. Trends Biochem Sci 23: 213–216, 1998.
43. Zhao J, Wang H, Dai C, Wang H, Zhang H, Huang Y, Wang S, Gaskin F, Yang N, Fu SM. P2X7 blockade attenuates murine lupus nephritis by inhibiting activation of the NLRP3/ASC/caspase 1 pathway. Arthritis Rheum 65: 3176–3185, 2013.
44. Zhuang S, Kinsey GR, Yan Y, Han J, Schnellmann RG. Extracellular signal-regulated kinase activation mediates mitochondrial dysfunction and necrosis induced by hydrogen peroxide in renal proximal tubular cells. J Pharmacol Exp Therap 325: 732–740, 2008.
45. Zhuang S, Yan Y, Daubert RA, Han J, Schnellmann RG. ERK promotes hydrogen peroxide-induced apoptosis through caspase-3 activation and inhibition of Akt in renal epithelial cells. Am J Physiol Renal Physiol 292: F440–F447, 2007.
46. Zhuang S, Yan Y, Han J, Schnellmann RG. p38 kinase-mediated transactivation of the epidermal growth factor receptor is required for dedifferentiation of renal epithelial cells after oxidant injury. J Biol Chem 280: 21036–21042, 2005.